Apparently, millions of Americans -- including those at a low-risk of heart attack -- should be on the cholesterol-reducing drugs. In my opinion, this is scary. Don't get me wrong -- statins are a wonderful thing and have helped many, many people. But we are a very medicated society and the fact that the medical community feels the need to medicate the low-risk population is frightening. Especially when healthy living could solve many of the same problems.

People with high cholesterol aren't the only ones who should be paying attention to their numbers. Even if your cholesterol falls in healthy ranges, you should still be taking proactive measures to manage it:

• Exercise regularly. Aerobic exercise increases your HDL cholesterol. HDL (high-density lipoprotein) is the "good" cholesterol because it helps carry the bad cholesterol out of your blood stream. Your HDL levels should be greater than 40 mg/dl.

Source

September is National Cholesterol Awareness Month, so take some time this month to educate yourself on cholesterol -- the good, the bad, and what you can do about it.

• Get tested. If you don't know your cholesterol levels, visit your doctor. Ask your doctor to explain the results and give you some recommendations if your cholesterol levels needs improvement. Chris recently posted a good overview of the different types of cholesterol and some general guidelines for healthy ranges.
  
• Eat heart-healthy foods. Choose plenty of whole grains, healthful fats (monounsaturated and polyunsaturated), lots of fruits and vegetables, and lean protein. Also, remember to minimize your sodium intake.

Source

A medication frequently prescribed for high cholesterol came under fire a few months ago when a trial showed the medication -- a combination of simvastin and ezetimibe -- worked no better than simvastin alone. Simvastin is a statin designed to lower LDL cholesterol; ezetimibe is another medication that should lower LDL in another way.

The results of the trials regarding the efficacy of Vytorin are being discussed at the American College of Cardiology's annual meeting this week. At this point, researchers aren't entirely sure if the results of the trial are indicative of how Vytorin would affect those with mildly high cholesterol or those who are newly diagnosed; all the participants in the study had very high cholesterol and had been under treatment for years.

Source

It's interesting to see that Merck, the pharmaceutical giant, wants to make its Mevacor cholesterol-lowering drug available as an over-the-counter drug, but that is precisely what is happening.

However, the FDA wonders if making the drug available to anyone who wants it will lead to many patients taking the drug who really do not need it.

It's hard to imagine folks without high cholesterol problems seeking our Mevacor at the local Wal-Mart, but of course this would happen in an age of "fix this" medicines and instant gratification health environments.

Case in point -- only 20 percent of potential patients interviewed by Merck answered all questions correctly when quizzed about proper usage of Mevacor.

Source